Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Commends Oxford BioDynamics for Developing a Novel Biomarker Discovery Platform, EpiSwitch™ - The utility of EpiSwitch™ in industrial settings distinguishes it from peer solutions - /
Frost & Sullivan Commends Oxford BioDynamics for Developing a Novel Biomarker Discovery Platform, EpiSwitch™


PRZOOM - /newswire/ - Mountain View, CA, United States, 2016/03/22 - The utility of EpiSwitch™ in industrial settings distinguishes it from peer solutions - /

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Based on its recent analysis of the biomarker discovery technology market, Frost & Sullivan recognizes Oxford BioDynamics Limited (OBD) with the 2015 European Frost & Sullivan Award for Technology Innovation. OBD’s novel biomarker discovery platform, EpiSwitch™, accelerates the discovery rate of biomarkers to facilitate a higher and more robust output of diagnostic and prognostic tests for pharmaceutical companies and therefore more effective patient care. The EpiSwitch™ finds application across a range of disease groups, including cancer, inflammatory, metabolic and neurodegenerative diseases.

OBD’s EpiSwitch™ detects chromosome confirmation signatures that enable clinicians to study and accurately identify genomic change. However, the advantage that really sets OBD apart in the pharmaceutical space is that it is the only company with a patented and established biomarker discovery platform for industrial use. It can non-invasively screen for biomarkers and provide results rapidly since it requires less than four hours for sample processing. This speed places it leagues ahead of competing solutions, which are viable for academic purposes but unable to replicate their success in an industrial setting.

“Unlike proteomic, metabolomics and gene expression platforms that require a reference frame of healthy levels, and therefore increase the complexity of comparison during the validation process, EpiSwitch™ is stable and binary,” said Frost & Sullivan Research Analyst Madhumitha Rangesa. “This eliminates the need for a reference frame.”

OBD currently offers EpiSwitch™ in three variants the EpiSwitch™ Array, next-generation sequencing (NGS) platform, and the polymerase chain reaction (PCR) platform. The NGS platform helps screen biomarkers for the selection of the best candidates for further stratification, while the PCR platform is employed at a later stage, such as post-stratification, where it aids the development of a cost-effective and robust biomarker diagnostic.

Meanwhile, OBD is making the most of the technology convergence trend by combining machine-learning algorithms with biomarker discovery. These algorithms enable pattern recognition, which helps them detect specific transcription unit structures in the DNA. Through such algorithms, the EpiSwitch™ platform generates a score that will segregate the patients into various groups, depending on their response to a specific set of markers, leading to the creation of a biomarker assay for OBD’s commercial partner.

Another important Mega Trend that influences OBD is the Big Data movement in genetics. The vast information that gets accumulated on the EpiSwitch™ platform will open up novel avenues of research for academic institutes, pharmaceutical companies and biotechnology companies, potentially leading to the discovery of new therapeutics.

Significantly, the EpiSwitch™ platform has won patents in Australia, New Zealand, Hong Kong, Japan, China, Singapore, South Africa and multiple European countries. This has increased the opportunities for technology licensing across Southeast Asia, Australia, Europe and the United States. OBD has already secured eight contracts with some of the leading pharmaceutical companies and expects to win another six over the next nine months, placing it in a unique strategic position in the global market.

OBD also has several collaborations with education institutes and biotechnology companies. It has partnered with the Ludwig Institute of Cancer Research to create stratification markers for melanoma, Mayo Clinic to establish predictive response biomarkers for anti-PD1 therapy in the treatment of melanoma, and the Scottish Early Rheumatoid Arthritis (SERA) consortium to design predictive response biomarkers for methotrexate for the treatment of rheumatoid arthritis.

“OBD was a spin-off company from Oxford University in 2007. It leveraged years of academic research to build a validated and efficient discovery platform that can be mobilized by pharmaceutical companies to produce a variety of precise diagnostic, monitoring and prognostic tests,” observed Madhumtiha. “OBD has succeeded in expanding the organization and entering the Asian market, cementing its position in the industry and as a market leader on the strength of its innovative biomarker discovery platform.”

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry, and the positive impact on brand perception.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Oxford BioDynamics
Oxford Biodynamics Limited ( is a healthcare service company offering a novel patented platform technology in the field of aberrant gene expression and epigenetics. The patented EpiSwitch™ platform technology detects epigenetic regulatory signature changes driving phenotypical changes between normal and abnormal conditions at the loci implicated in the onset and progression of the disease, and /or response to the treatment. The EpiSwitch™ biomarker discovery platform identifies Chromosome Conformation signatures (CCSs), which define the initial regulatory process in integrating environmental clues into the epigenetic and transcriptional machinery. As such CCSs are the primary step in a cascade of gene deregulation due to pathology and is there fore able to deliver a unique and robust epigenetic platform technology to improve Healthcare outcomes.

The Company is based in Oxford, UK, with Subsidiaries in Singapore, Malaysia and Australia.

About Frost & Sullivan
Frost & Sullivan (, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Frost & Sullivan Commends Oxford BioDynamics for Developing a Novel Biomarker Discovery Platform, EpiSwitch™

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan | Oxford BioDynamics Ltd
Contact: Mireya Espinoza - 
210-247-3870 mireya.espinoza[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.

  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today